IRCT2017011931229N2招募中未知
Evaluation of the neuroprotective effect of N-Acetyl-Cysteine in patients with cerebrovascular accident in years 95-96 in firoozgar hospital.
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 80 years（—）
- 性别
- All
入选标准
- •all admitted patients with first attack of mild to moderate CVA according to NIHSS between 0-16; admitted patients within first 24 hours of onset of CVA.
- •Exclusion criteria:Hemorrhagic stroke; Severe Hepatic or renal failure. ( creatinine clearance less than 30 mg/dl); History of Vasculitis; Allergy to N- acetyl- cystein; Alzheimer or dementia due to any cause; Coexistent other neurologic disorders.;Past history of CVA;Age more than 80 years; Diseases that affect on MMP-9 level. e.g neuropsychiatric disorders like schizophrenia and bipolar disorder,epilepsy and mutiple sclerosis; Intravenous or intaarterial r-tPA injection.
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Evaluation of the protective effect of N-Acetyle-Cysteine versus placebo on the heart of diabetic patients undergoing CABGCoronary artery bypass graft.Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectorisI25.70IRCT20120215009014N202Hamedan University of Medical Sciences240
已完成
3 期
Investigating the efficacy and safety of N-Acetyl Cysteine (NAC) inhalation spray in controlling the symptoms of patients with COVID-19IRCT20080901001165N55Bagheiat-allah University of Medical Sciences250
已完成
不适用
The effect of N-acetyl cysteine and vitamin C on kidney in patients undergoing open heart surgery.Condition 1: Renal failure. Condition 2: coronary vessel disease.Acute renal failureAtherosclerosis heart diseaseIRCT2014072815102N4Vice chancellor for research affairs, Shiraz University of Medical Sciences84
已完成
不适用
Protecting effect of N-acetylcysteine on myocard during CABGAtherosclerotic cardiovascular disease.Atherosclerotic cardiovascular diseaseIRCT201211062883N3Mazandaran Uiversity of Medical Sciences and Health Services60
已完成
2 期
Evaluation of the neuroprotector effect of an extract of stem bark of Mangifera indica L. (Vimang®) in patient with Spinocerebellar Hereditary Ataxia Type 2Spinocerebellar Hereditary Ataxia Type 2Spinocerebellar AtaxiasCerebellar AtaxiaAtaxiaSpinocerebellar DegenerationsCerebellar DiseasesHeredodegenerative Disorders, Nervous SystemNeurodegenerative DiseasesNervous System DiseasesSpinal Cord DiseasesDyskinesiasNeurologic ManifestationsGenetic Diseases, InbornBrain DiseasesRPCEC00000005Center of Pharmaceutical Chemistry20